Salta al contenuto
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Avanzata
  • Clonal heterogeneity in differ...
  • Citazione
  • Invia SMS
  • Invia email
  • Stampa
  • Esporta il record
    • Esporta a RefWorks
    • Esporta a EndNoteWeb
    • Esporta a EndNote
  • PLink permanente
Clonal heterogeneity in differentiation response and resistance to the IDH2 inhibitor enasidenib in acute myeloid leukemia

Clonal heterogeneity in differentiation response and resistance to the IDH2 inhibitor enasidenib in acute myeloid leukemia

Dettagli Bibliografici
Autori principali: Quek, L, David, M, Kennedy, A, Metzner, M, Amatangelo, M, Shih, A, Stoilova, B, Karamitros, D, Quivoron, C, Heiblig, M, Willekens, C, Saada, V, Peniket, A, Bernard, O, Agresta, S, Yen, K, Stein, E, De Botton, S, Thakurta, A, Levine, R, Penard-Lacronique, V, Vyas, P
Natura: Conference item
Pubblicazione: American Society of Hematology 2017
  • Posseduto
  • Descrizione
  • Documenti analoghi
  • MARC21

Documenti analoghi

  • Clonal heterogeneity of acute Myeloid Leukemia treated with the IDH2 inhibitor Enasidenib
    di: Vyas, P, et al.
    Pubblicazione: (2018)
  • Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response
    di: Amatangelo, MD, et al.
    Pubblicazione: (2017)
  • Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
    di: Stein, EM, et al.
    Pubblicazione: (2017)
  • Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML
    di: Risueño, A, et al.
    Pubblicazione: (2024)
  • Molecular features associated with response to enasidenib plus azacitidine in newly diagnosed IDH2-mutated acute myeloid leukemia
    di: Risueño, A, et al.
    Pubblicazione: (2023)

Opzioni di ricerca

  • Ultime ricerche
  • Ricerca avanzata

Cerca

  • Scorri il catalogo
  • Scorri in ordine alfabetico
  • Esplora selezioni
  • Materiali riservati (per i corsi)
  • Nuovi documenti

Serve aiuto?

  • Suggerimenti per la ricerca
  • Chiedi al bibliotecario
  • FAQ